A PRISMA-ScR scoping review of randomized controlled trials (searching PubMed, CINAHL, and Web of Science through Jan 2026) found the evidence base for AI-enabled nutrition assessment and insulin decision support in Type 1 Diabetes (T1D) is small, largely limited to high-income settings, and shows mixed CGM outcome improvements. No serious safety events were reported, but small samples, short follow-up, and inconsistent safety reporting make real-world safety and utility uncertain.

Why It Matters To Your Practice

• AI tools are already entering diabetes care workflows, but the RCT evidence supporting clinically meaningful benefit is thin and context-limited.

• Mixed CGM improvements mean performance may vary by tool, patient population, and implementation setting.

• Inconsistent safety reporting creates blind spots for hypoglycemia risk, dosing errors, and downstream harm—even when “no serious events” are reported.

Clinical Implications

• Use AI outputs as decision support—not decision replacement—especially for insulin dosing and meal-related recommendations.

• When selecting or piloting tools, prioritize those that report clear safety endpoints, monitoring plans, and escalation pathways for out-of-range glucose.

• Set patient expectations: benefits may be modest or variable; reinforce core self-management skills and confirmability of recommendations.

Insights

• Trials were concentrated in high-income settings, limiting generalizability to diverse populations and low- and middle-income countries.

• Most studies used CGM-derived outcomes to assess “utility,” leaving gaps in patient-centered outcomes (burden, confidence, quality of life) and workflow impact.

• Short follow-up and small sample sizes limit detection of uncommon but clinically important safety issues.

The Bottom Line

• AI for nutrition/insulin decisions in T1D has promising use cases, but current RCT evidence is limited and mixed.

• Until larger, longer, real-world studies with standardized safety endpoints are available, adopt cautiously with robust monitoring and clear accountability.